FunPep Past Earnings Performance
We're still processing the latest earnings report of this company
Past criteria checks 0/6
FunPep has been growing earnings at an average annual rate of 31%, while the Biotechs industry saw earnings growing at 11.1% annually. Revenues have been declining at an average rate of 100% per year.
Key information
31.0%
Earnings growth rate
41.6%
EPS growth rate
Biotechs Industry Growth | 31.9% |
Revenue growth rate | -100.0% |
Return on equity | -33.9% |
Net Margin | n/a |
Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Revenue & Expenses Breakdown
How FunPep makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 24 | 0 | -727 | 265 | 455 |
31 Mar 24 | 0 | -760 | 267 | 484 |
31 Dec 23 | 0 | -933 | 267 | 680 |
31 Dec 22 | 1 | -1,172 | 222 | 912 |
Quality Earnings: 4881 is currently unprofitable.
Growing Profit Margin: 4881 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Unable to establish if 4881's year-on-year earnings growth rate was positive over the past 5 years as it has been trading publicly for less than 3 years.
Accelerating Growth: Unable to compare 4881's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 4881 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (4%).
Return on Equity
High ROE: 4881 has a negative Return on Equity (-33.88%), as it is currently unprofitable.